IDEXX Laboratories heads into its May 5 Q1 earnings call with the stock under pressure, short interest at a one-month high, and analysts cutting targets — a convergence that raises the stakes on next week's print.
The most visible story of the week is from the Street. Analyst targets have been moving in one direction. UBS slashed its price target to $640 from $730 on April 28, maintaining a Neutral rating, just two weeks after Citigroup started coverage at a matching $650 Neutral. Both joined Stifel, which trimmed to $675 from $775 at end of March while keeping a Buy. The pattern is clear: even bulls are pulling targets lower. The mean consensus target is now $724.50 — roughly 31% above Tuesday's close of $553.66 — implying the Street still sees significant value at current levels, but the direction of travel for individual targets has been consistently downward since the last earnings release in February. Bulls point to IDEXX's durable franchise in veterinary diagnostics, its sticky reference lab and point-of-care ecosystem, and a structurally growing global pet population. Bears flag the premium valuation, softening pet-visit volumes under economic pressure, and competitive heat from names like ZTS. With the stock off 15% year-to-date, the debate has sharpened.
Short interest has been quietly building, and the trend is harder to ignore heading into an event. The short position climbed roughly 21% over the past month, reaching 2.54% of the free float — not a crowded short by any measure, but the rate of accumulation is notable. ORTEX daily estimates put the build-in as a steady grind from around 1.85 million shares in late March to just over 2.03 million shares this week. The borrow market, however, tells a calmer story. Cost to borrow has actually eased — from a month-high of around 0.51% in early April down to 0.37% now, a 25% drop over the week alone. Availability remains ample, with the lending pool far from tight, reinforcing that this is deliberate directional positioning rather than a squeeze dynamic. The ORTEX short score sits at 35.4, well below levels that signal acute pressure, and has drifted modestly lower across the past two weeks.
Options positioning is not flashing alarm. The put/call ratio at 0.65 is just fractionally below its 20-day average of 0.66, and the z-score of –0.21 is effectively flat — options traders are neither rushing for downside protection nor leaning hard into calls ahead of results. The 52-week range for the PCR runs from 0.57 to 2.22, putting the current reading comfortably in the lower half — call-leaning territory. That sits in contrast with the short build, where new positions are being added without a matching hedging impulse in options. The two signals read as a mild but widening divergence: equity shorts are growing, but derivatives desks are relaxed.
Valuation has re-rated lower with the price. The P/E has slipped to 36.6x, down just under one turn over the past month, while EV/EBITDA is at 26.2x, off a full turn in thirty days. At 18x book, IDEXX still carries a rich absolute multiple — the stock has never been cheap — but the compression from above $650 to $553 has begun to erode the premium in relative terms. The EPS surprise factor score ranks in the 72nd percentile, suggesting a history of beating consensus, which matters heading into a print where the set-up is cautious. EPS momentum on a 12-month forward basis, however, ranks in the 22nd percentile — forward estimates have been drifting down, not up.
Earnings history adds texture here. The two prior prints from the early part of 2026 both produced negative one-day reactions — a 5.7% drop in February followed by a shallower 0.6% decline — with the five-day window similarly negative after each. That pattern of post-earnings softness has contributed to the cautious positioning now in place. The Q1 Earnings Call is confirmed for May 5. How much of the target-cut cycle is already baked in at $553 — and whether pet-health demand held up through the first quarter — is what traders will be listening for.
See the live data behind this article on ORTEX.
Open IDXX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
